Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure

Medical Science Monitor

Volumn 9, Issue 8, 2003, Pages

  Feola, Mauro ^a   Menardi, Endrj ^a   Ribichini, Flavio ^b   Vado, Antonello ^a   Deorsola, Antonella ^a   Ferrero, Valeria ^b   Visconti, Gianluca ^a   Milanese, Ugo ^a   Uslenghi, Eugenio ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Brain natriuretic peptide; Cardiopulmonary function; Congestive heart failure; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EXERCISE TEST; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNORADIOMETRIC ASSAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; TREATMENT OUTCOME;

AGED; ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; DIURETICS; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; SPIRONOLACTONE; VENTRICULAR FUNCTION, LEFT;

EID: 0141818324     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pitt B, Zannad F, Remme WJ et al: The effect of spironolactone on morbidity and mortality in patients with severe heart, failure. N Engl J Med, 1999; 341: 709-717
2. The RALES Investigators: Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop of diuretic for severe chronic congestive heart failure. Am J Cardiol, 1996; 78: 902-907
3. Boland DG, Abraham WT: Natriuretic peptides in heart failure. Congestive Heart Fail, 1998; 4: 23-33
4. Saito Y, Nakao K, Arai H et al: Atrial natriuretic peptide (ANP) in human ventricle: increased gene expression of ANP in dilated cardiomyopathy. Biochem Biophys Res Commun, 1987; 148: 211-217
5. Maeda K, Tsutamoto T, Wada A et al: Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 1998; 135: 825-832
6. McDonagh TA, Robb SD, Murdoch DR et al: Biochemical detection of left-ventricular systolic dysfunction. Lancet, 1998; 351: 9-13
7. Landray MJ, Lehman R, Arnold I: Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ, 2000; 320: 985-986
8. Troughton RW, Frampton CM, Yandle TG et al: Treatment heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet, 2000; 355: 1126-1130
9. Dunn BR, Ichikawa J, Pfeffer JM et al: Renal and systemic haemodynamic effects of synthetic atrial natriuretic peptide in the anaesthetised rat. Circ Res, 1986; 59: 237-246
10. Kono M, Yamauchi A, Tsuji T et al: An immunoradiometric assay for brain natriuretic peptide in human plasma. Kaku Igaku Gijutsu, 1993; 13: 2-7
11. Yashue H, Yoshimura M, Sumida H et al: Localization and mechanism of secretion of B-type of natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203
12. Schiller NB, Shah PM, Crawford M et al: Recommendation for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards. Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocadiogr, 1989; 2: 358-367
13. Fletcher GF, Balady G, Froelicher VF: Exercise standards: a statement for healthcare professionals from the American Heart Association Writing Group. Special Report. Circulation, 1995; 91: 580-615
14. Opasich C, Pinna GD, Bobbio M et al: Peak exercise oxygen consumption in chronic heart failure: toward efficient use in the individual patient. J Am Coll Cardiol, 1998; 31: 766-775
15. Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J AM Coll Cardiol, 2003; 41: 211-4
16. Tsutamoto T, Wada A, Maeda K et al: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodelling in patients with congestive heart failure. J Am Coll Cardiol, 2001; 37: 1228-1233
17. Yoshimura M, Yasue H, Okamura K et al: Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation, 1993; 87: 464-469
18. Morita E, Yasue H, Yoshimura M et al: Increased plasma level of brain natriuretic peptide in patients with acute myocardial infarction. Circulation, 1993; 88: 82-91
19. Yasue H, Yoshimura M, Sumida H et al: Localization and mechanism of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203
20. Downing SE, Lee JC: Contribution of alpha-adrenoreceptor activation to the pathogenesis of norepinephrine cardiomyopathy. Circ Res, 1983; 52: 471-478
21. Lee JC, Spondenberg DP: Role of alpha 1-adrenoreceptors in norepinephrine-induced cardiomiopathy. Am J Pathol, 1985; 121: 316-321
22. Kawani K, Hata K, Takaoka H et al. Plasma Brain Natriuretic Peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment. Am Heart J, 2001; 141: 925-932
23. Mancini DM, Eisen H, Kussmaul W et al: Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation, 1991; 83: 778-786
24. Cicoira M, Zanolla L, Rossi A et al: Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol, 2002; 40: 304-10
25. Working Group on Cardiac Rehabilitation and Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise testing in chronic heart failure patients. Eur Heart J, 2001; 22: 37-45
26. Franciosa J, Leddy C, Wilen M et al: Relation between hemodynamic and ventilatory responses in determining exercise capacity in severe congestive heart failure. Am J Cardiol, 1984; 53: 127-134
27. Cohen-Solal A, Logeart C, Guiti C et al: Cardiac and peripheral responses to exercise in patients with chronic heart failure. Eur Heart J, 1999; 20: 931-945